Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 3,401–3,500 of 3,636
Evaluation of bempedoic acid in elderly patients: real-world evidence from the REALIST study
Muscoli, S., Marco, E. D., Puttini, F., Ghezzi, S. S., Ifrim, M., Amtaeh, M., Renga, E. M., Cappello, C. M., Barone, G., Chiricolo, G., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1675989 · Cited by 1
Fineblit, S., Vickers, D. M., & Campbell, D. J. T. (2026) · CJC Open · doi:10.1016/j.cjco.2026.03.002
“…à 1,74]; p < 0,001) ainsi qu’un taux plus � elev � e de mal-adies cardiovasculaires ath � eroscl � ereuses (RC ajust � e : 5,58, IC à 95 % [1,63 à 14,50]; p = 0,003), et � etaient plus susceptibles d’avoir consult � e un sp � ecialiste (RC ajust � e : 6,64, IC à 95 % [2,69 à 21,50]; p < 0,001).”
InfluentialSteen, D. L., Ray, K. K., Khan, I., Catapano, A. L., Bhatt, D. L., Koumas, A., Pol, K., & Giugliano, R. P. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.007
Self-citationFunctional impact of PCSK9 variants on LDL uptake in a knockout hepatic model
Li, H., Liu, H., Xu, W., Zeng, Y., Huang, P., Guo, J., Cai, B., Chen, Y., Lin, Y., & Zhang, C. (2026) · PLoS ONE · doi:10.64898/2026.03.13.711724
Chen, Z., Ma, S., Zhang, J., Zhang, R., Zhou, M., Li, C., Chen, Y., Wang, H., & He, Y. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-112947
Berrandou, T.-E. (2026) · Annales d Endocrinologie · doi:10.1016/j.ando.2026.102509
Bandt, D. D., Guez, A., Catala, I., & Pondaven, S. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.02.011
Oliveira, J. R. C. D. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014177 · Cited by 1
Celeski, M., Golino, M., Muro, F. M. D., Martino, G., Bernardi, M., Sasso, L. L., Gioia, G. D., Biccirè, F. G., Rubbio, A. P., Vecchione, C., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.058
From residual risk to real risk: why implementation fails when we misunderstand the problem
Shapiro, M. D. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf665
The paradox of asymptomatic carotid atherosclerosis in women: gender differences
Giorgio, A. D., Biferali, B., D’Angelo, M., Urbani, I., Nesci, A., Carnuccio, C., Santoro, L., D’Alessandro, A., & Santoliquido, A. (2026) · Journal of Ultrasound · doi:10.1007/s40477-026-01145-9
Peng, A. W., Plott, C. F., Zahid, S., Kassamali, A. A., Jones, L. K., Campbell‐Salome, G., Davis, E. N., Head, L., Kalich, B. A., Spitz, J. A., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107440 · Cited by 1
Clinical Trials in Cardiovascular Medicine
Nogueira, A., Zimerman, A., & Moura, F. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00091-1
Approches biochimique, épidémiologique et clinique du métabolisme intégré de la Lipoprotéine (a)
Blanchard, V. (2020) · theses.fr (ABES) · doi:10.70675/3ce7e0fdzecbaz4b18zaf08z34fb33c163ff · Cited by 1
Etude du rôle de la protéine PCSK9 dans la cellule bêta pancréatique
Saitoski, K. (2021) · theses.fr (ABES) · doi:10.70675/58b8c006z57e2z47a2zbb66z1e469544d6a5
Le rôle du récepteur aux LDL et de PCSK9 dans le diabète de type 2
Ramin‐Mangata, S. (2020) · theses.fr (ABES) · doi:10.70675/26622ba5zb0fcz4d30za6e6z5c95a0b5a33d
Wang, Q., Fang, H., Cui, W., & Zhang, G. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02943-0
“C targets [11–20].”
Umezono, R., Kato, S., Yasuda, N., Sawamura, S., Ishiwata, Y., Horita, N., & Utsunomiya, D. (2026) · Coronary Artery Disease · doi:10.1097/mca.0000000000001639
Deo, S. V., Ciminata, G., Mahalwar, G., Salerno, P. R. V. D. O., McAllister, D., Elgudin, Y. E., Orkaby, A. R., Virani, S., Fremes, S. E., Rajagopalan, S., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.124.040272
Niazi, S. K. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s576169
Dyslipidaemia and cardiovascular risk – Key considerations in South Asians
Chauhan, A., Sahota, S., Jegatheeswaran, L., Johal, H. K., Minhas, R., Patel, P., Gupta, P., Patel, V., Banerjee, A., Patel, K., et al. (2026) · Clinical Medicine · doi:10.1016/j.clinme.2026.100571
“46,47 Initial evidence suggests that outcomes across ethnicity are similar.”
Kardiovaskuläre Pharmakotherapie im Zeitalter RNA-basierter Präzisionsmedizin
Derda, A. A., & Hohneck, A. L. (2026) · Herz · doi:10.1007/s00059-026-05375-9
Ruscica, M., Tassistro, E., Rizzuto, A. S., Macchi, C., Orlando, A., Rebora, P., Carugo, S., Parati, G., Giussani, M., Corsini, A., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104754
Sokolova, I. V., Averina, I. A. A., Konovalchuk, N. A., Chernigovskiy, R. A., & Larkina, M. V. (2026) · Russian Journal of Cardiology and Cardiovascular Surgery · doi:10.17116/kardio20261902158 · Cited by 1
Davies, J. L., Zhang, Y., Patabendi, I., Ramachandran, S., & Baharani, J. (2026) · BioMed · doi:10.3390/biomed6020011
Kowalczys, A., Marlęga-Linert, J., Gruchała, M., & Mickiewicz, A. (2026) · Cardiac failure review · doi:10.15420/cfr.2025.46
“83 Nevertheless, the exclusion criteria were NYHA class III or IV HF or LVEF 25%.”
Genetic and clinical risk factors for recurrent events among patients with coronary artery disease
Halford, J. L., Koyama, S., Sui, Y., Cho, S. M. J., Bellomo, T. R., Misra, A., Patel, A. P., Hornsby, W., Fahed, A. C., & Natarajan, P. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101638 · Cited by 2
“Secondary prevention trials have reported ~10% and ~30% event rates at three and six years of follow-up, respectively, reflecting persistent residual risk [37 – 39].”
Schwartz, G. G., Szarek, M. J., Cobbaert, C. M., Ruhaak, L. R., Schwertfeger, M., Bhatt, D. L., Bittner, V., Goodman, S. G., Harrington, R. A., Stevanovic, I., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101643 · Cited by 1
“Baseline characteristics were well-balanced between treatment groups and similar to those of the full study cohort [11], except that patients comprising the analysis cohort were less likely enrolled at Central or Eastern European sites and more likely enrolled at North American sites.”
Self-citationEvidence‐Based Recommendations on the Use of Inclisiran in Patients With Chronic Kidney Disease
Sharma, S., Kalra, S., Sahay, M., Kapoor, N., Nagendra, L., Verma, H., Sharma, N., Verma, M., RAJU, S. B., & Tang, S. C. W. (2026) · Nephrology · doi:10.1111/nep.70206
“Table 1 highlights the landmark trials of lipid-lowering therapies in CKD [12, 14–23].”
Lp(a) at the Crossroads: New Strategies to Reduce Residual Cardiovascular Risk
Kaushal, V., Brar, P. C., & Kohn, B. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01404-4
Parameswaran, T., Hooper, A. J., & Burnett, J. R. (2026) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2026.2662915
“Both FOURIER (evolocumab) in patients with acute coronary syndrome [5] and ODYSSEY Outcomes (alirocumab) in patients with stable ASCVD [6] demonstrated comparable reductions of ~15% in major adverse cardiovascular events (MACE).”
Peripheral artery disease in diabetes
Amin, S., Fukaya, E., & Athavale, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1811582 · Cited by 5
“For example, PCSK9 inhibition with evolocumab signi fi cantly reduced MALE in the FOURIER trial, and a prespeci fi ed analysis of the ODYSSEY OUTCOMES trial showed reduced PAD events with alirocumab on a background of intensive statin therapy (49, 50).”
Nonstatins for LDL-C lowering: An expansion whose time has come
Saseen, J. J., & Dixon, D. L. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.04.017
Impact of early initiation of PCSK9I monoclonal antibodies after acute coronary syndrome
Goel, P. K., Kapoor, A., Jain, K. J., Thachathodiyl, R., Reddy, V., Guleria, V. S., Bhalla, N., & Sasidharan, S. (2026) · Indian Heart Journal · doi:10.1016/j.ihj.2026.04.013
Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment
Yu, L., Xiang, B., Ren, Y., Li, Y., Xie, J., & Zhou, X. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047923 · Cited by 1
“7,8 While most individuals tolerate statins well, approximately 9.1% of patients experience side effects, including liver enzyme abnormalities, muscle pain, and cognitive impairment, that necessitate dose adjustment or alternative therapies.”
InfluentialWang, J., Zhou, X., Liu, Y., Xu, J., Long, Y., Hu, S., Wang, C., Yan, L., Yang, C., Wang, L., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102212
Zhang, F., & Liao, Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1790509 · Cited by 3
“Many of the most effective contemporary therapies—PCSK9 inhibition, long-acting RNA-based agents, and emerging Lp(a)- lowering modalities—raise cost and access challenges (8, 9, 56–60, 63–65, 78, 79).”
Familiäre Hypercholesterinämie – wann daran denken – wie vorgehen?
Vogt, A. (2026) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-026-00304-x
“Fürdiebeidenmo-noklonalen Antikörper Evolocumab und Alirocumab liegen Endpunktstudien vor, die neben der signifikanten Senkung von LDL-C und der hervorragenden Verträg-lichkeit auch zeigen, dass die Ereignisre-duktion umso ausgeprägter ist, je weiter LDL-Cgesenktwird[23,24].”
Wen, S., Wang, C., Xu, Z., Chen, L., He, Y., Ren, Y., Yuan, Y., Li, Y., Dong, M., Gong, M., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03164-6 · Cited by 1
“Alirocumab in ODYSSEY OUTCOMES (2018) similarly lowered MACE by 15% (HR 0.85, 95% CI 0.78–0.93), reinforcing the class's efficacy in post-acute coronary syndrome settings [68].”
InfluentialThe Impact of Current and Emerging Therapies on Lipoprotein(a)
Nicholls, S. J., & Nelson, A. J. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.96 · Cited by 1
Stéphan, D., Zamperini, C., & Cordeanu, E. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200646
“PCSK9 inhibitors (evolocumab, alirocumab) have demonstrated robust LDL-C lowering and cardiovascular event reduction in secondary prevention trials (FOURIER, ODYSSEY OUTCOMES), including in older subgroups [34,35].”
Wu, Y., Yeh, C., Hsu, C.-Y., Lin, C. Y., Huang, C., Tang, S., Huang, Y. T., Lin, C. Y., Yu, C.-H., Huang, C. Y., et al. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.04.111 · Cited by 1
An, W., Chen, S., Wang, J., Yin, X., Du, C., & Ding, F. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05892-9
“PCSK9 inhibition can reduce Lp(a), but usually only modestly, and most routine-care regimens do not normalize high Lp(a) [12, 22, 30].”
The secretory PCSK family in cardiovascular disease and beyond
Seidah, N. G. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120716 · Cited by 1
Almahmeed, W. A., Sabbour, H. M., Shantouf, R. S., Aljaberi, A. K., Tamimi, H. E., Lootah, F. B., Sayed, N. A., Ali, J. A., Akbar, M. A. J., Shehab, A., et al. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100569 · Cited by 1
“…showed that alirocumab reduced MACE in patients with recent acute coronary syndrome who continued to have elevated atherogenic lipoproteins despite maximal statin therapy [159,160], while the FOURIER trial demonstrated greater absolute benefit from evolocumab in those with elevated Lp(a) [161].”
Bhatti, M. I., Safiullah, M., Qadri, M., Butt, A. A., & Ahmed, R. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00797-6
“Cre-atine kinase elevations showed a minimal risk ratio (1.36), which contrasts with the 10–15% incidence of myalgia reported in Asian patients on statins [42].”
InfluentialLipid lowering in coronary artery disease – not just statins
Han, J., Masmanian, E., Wang, T., & Chua, T. P. (2026) · Clinical Medicine · doi:10.1016/j.clinme.2026.100594 · Cited by 1
Musumeci, G., Pradelli, L., Lee, K., & Povero, M. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01559-7
“In the ODYSSEY OUTCOMES trial, alirocumab reduced recurrent ischemic events in patients post-acute coronary syndrome (ACS) on high-intensity statins (hazard ratio [HR]: 0.85; 95% confidence interval [CI] 0.78–0.96) [7].”
InfluentialBabić, S., Bastać, M., & Nešović, P. (2026) · Timocki medicinski glasnik · doi:10.5937/tmg2601027b
Yao, J., Sun, Q., Liu, D., Lin, J., & Wang, W. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05931-5
Metabolic Implications in Cardio-Renal Syndromes
Timar, B., Gaiţă, L., Avram, V. F., & Braha, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-25434-4_15
Trends in acute myocardial infarction mortality in the United States, 1999–2023
Zhu, J., & Pei, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1817513 · Cited by 2
“…ACS is superior to a moderate-intensity strategy (35); the IMPROVE-IT trial showed that adding ezetimibe on top of statin therapy can further reduce event risk (36); later, the FOURIER and ODYSSEY OUTCOMES trials extended evidence for PCSK9 inhibitors to lower residual-risk management (37, 38).”
Chinese expert consensus on the choice of initial cholesterol-lowering strategy
Wu, N., Wang, X., Ye, P., Chen, H., Chen, Z., Zhao, D., Dq, P., Guo, Y., Gao, Y., Yang, J.-G., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1798787
“…Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab (ODYSSEY OUTCOMES) trials consistently confirmed that adding a PCSK9 inhibitor to statin therapy can reduce the risk of MACE by approximately 15% (Sabatine et al., 2015; Schwartz et al., 2018).”
Schwartz, G. G. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5132
Self-citationChapman, M. J., Thérond, P., & Meikle, P. J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109050 · Cited by 1
Single-Cell Analysis in Pharmacological Research for Blood Lipid Disorders
Dang, H.-L., Hoang, D.-A., & Chu, D.-T. (2026) · Springer eBooks · doi:10.1007/978-981-95-9789-5_16
Freijo, M. D. M., Cardona, P., Castellanos, M., de Torres-Chacón, R., Gil-Núñez, A., Guillán, M., Martínez‐Sánchez, P., Palacio-Portilla, E. J., Purroy, F., Segura, T., et al. (2026) · Neurología · doi:10.1016/j.nrl.2026.502076
A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries
Liu, H., Li, S. N., & Li, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1800502
“For alirocumab, the ODYSSEY OUTCOMES trial demonstrated that in patients with recent acute coronary syndrome, treatment not only lowered MACE risk but also significantly reduced all-cause mortality (Schwartz et al., 2018).”
Freijo-Guerrero, M., Cardona, P., Castellanos, M., de Torres-Chacón, R., Gil-Núñez, A., Guillán, M., Martínez-Sánchez, P., Palacio-Portilla, E. J., Purroy, F. F., Segura, T., et al. (2026) · Neurología (English Edition) · doi:10.1016/j.nrleng.2026.502076
Tsai, H., Hsu, J., Loh, C., & Huang, H. (2026) · Pharmaceuticals · doi:10.3390/ph19050750
“Clinical studies have demonstrated that PCSK9 inhibitors reduce ischemic cardiovascular events both as monotherapy and in combination with statins [5,6].”
Badimón, L., Vilahur, G., & Mendieta, G. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120777
Pescol, F., Buonocore, T. M., Tibollo, V., Failla, G., Traversi, E., Rovere, M. T. L., Sacchi, L., Ricciardi, W., & Bellazzi, R. (2026) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2026.106509 · Cited by 1
Weekly Journal Scan: Translating LDL-cholesterol targets into vascular event reduction
Pedicino, D., & Volpe, M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag369
PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia
Woźniak, A., Pawlos, A., Gorzelak‐Pabiś, P., Broncel, M., Bukowska, B., & Woźniak, E. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71206
“Major trials (FOURIER and ODYSSEY OUTCOMES) demonstrated that alirocumab and evo-locumab improve cardiovascular outcomes when added to statin therapy and show no safety differences compared to placebo [4, 5].”
Youseif, A. L., Younis, A. F., Elmezayen, Z. W., Eldahrawy, M., Hammad, N., Hamed, B. M., Saleh, A. R., Mohamed, A. A., Saad, O. A., Ramadan, A. M., et al. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04081-z
Pharmacologic Therapy to Prevent CV Disease in High-Risk Youth
Hartz, J. C., Degen, M. G., & Ware, A. L. (2026) · Contemporary cardiology · doi:10.1007/978-3-032-14256-6_11
Dosage of lipoproteins for risk management according to guidelines
Bonnin, C., Fourgeaud, C., Mahé, G., Ezzaki, K., Gras, M., Himpens, F. X., Jacquet, R., Khider, L., Mirault, T., Poggi, J. N., et al. (2026) · Vascular Diseases · doi:10.1016/j.vasdi.2026.05.001
Боднар, В., Єремєєва, Є., Мандрик, О., & Антофійчук, М. П. (2026) · ГРААЛЬ НАУКИ · doi:10.36074/grail-of-science.01.05.2026.116
Mesquita-Lousada, A., Rocha-Melo-Sousa, A., Teixeira, C., Guimarães, T. R., Marques-Vieira, M., Andrade, J. P., Ribeiro, H., Neiva‐Sousa, M., & Rocha-Neves, J. P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114205
“[35], or very high cardiovascular risk (>20% 10-year ASCVD risk), are precisely those who would derive the greatest absolute benefit from PCSK9 inhibitors (~60% additional LDL-C reduction and number needed to treat as low as 20–30 to prevent one major CV event over 5 years) [7].”
InfluentialParcero-Valdés, J. J., Magaña-Serrano, A., Arias‐Mendoza, A., Narváez-Oríani, C. A., Altamirano-Cardoso, E., Barrios, V., Díaz-Barreiro, L. A., López, A. A. P., & Gómez-Álvarez, E. (2026) · Cardiovascular and Metabolic Science · doi:10.35366/123178
Tan, R. S., Yap, J. J. L., Yeo, C., Poh, K. K., Yan, P. C., Chia, P. L., Lim, M. C. L., Foo, D. C. G., Jafary, F. H., & Koh, N. S. Y. (2026) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2025459
Modani, S. M., Rampelly, S. K., Palagiri, S., Ibrahim, S. B., & Ramachandiran, S. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200657
“Importantly, immunohistochemical and imaging studies show preferential accumulation of Lp(a) within atherosclerotic lesions, suggesting active biological participation in plaque evolution rather than passive lipid transport [43,48].”
Rossi, B., & Masson, W. M. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103383
Schäfer, A., Grosshennig, A., Theis, L., Schindler, C., Grahl, E., Stichtenoth, D., König, T., Geller, W., Schmidt, H., Bavendiek, U., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1755590
“…potent statins plus ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors such as evolocumab or alirocumab have shown additive clinical benefit in cardiovascular outcome trials (9, 10), but are not widely available for the overall population due to prescription limitations.”
Management of Large Artery Atherosclerosis
Wabnitz, A. (2026) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001712
Zayed, J. A., Al‐Awamleh, N. A., Hamad, M., Hdaib, M. I. M., & Ayesh, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70944 · Cited by 3
“Evolocumab (140 mg, 420 mg), alirocumab (75 mg, 150 mg) and inclisiran (300 mg) were among the most effective therapies in LDL-C reduction, consistent with findings from FOURIER/earlier studies, ODYSSEY OUTCOMES and ORION-10/11 trials, respectively [9, 74, 75].”
Casu, G., Idini, C., Santoru, A., Serra, G., Bilotta, F., Poddighe, C., Merella, P., Murtas, V. D., Rubbino, F., Micheluzzi, V., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104820
Advances in the Diagnosis and Management of Acute Coronary Syndrome: A Clinical Review
Anand Sekar, G., Rai, D. P., Darji, B. L., Jain, N., Kumar, S., & Singh, R. (2026) · Cureus · doi:10.7759/cureus.110344
Roman, S., & Budoff, M. J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109058 · Cited by 1
Masana, L., Ribalta, J., & Ibarretxe, D. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00102-6
Lanthier, L., Perron, P.-N., Mutchmore, A., Plourde, M.-É., & Cauchon, M. (2026) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2026.05.017
Akinmolayemi, O., Oliva, A., Sartori, S., Vasa, D., Feng, Y., Sweeny, J. M., Hooda, A., Bhatt, D. L., Dangas, G., Mehran, R., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.05.044
Self-citationElectronic Health Record Alerts to Improve Lipid Lowering After a Recent Myocardial Infarction
Karalis, D. G., Richter, B., Hessen, S. E., Moeller, P., & Jones, L. K. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047116
Kwon, Y., Kim, N., Kim, D.-H., Kim, B., Park, J. S., Park, Y. J., Park, B. E., Kim, H. N., Lee, J. H., Yang, D. H., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06087-y
Fu, T., Yao, S., Zhang, S., & Linghu, H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1804585
“Monoclonal antibody inhibitors of PCSK9 (PCSK9i), including evolocumab and alirocumab, potently reduce LDL-C by 50% – 70% and have proven cardiovascular benefits in major outcome trials (10, 11).”
InfluentialJiang, M., Zhang, F., Ren, M., Li, Z., Xie, Z., & Sun, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1841513
“They demonstrated that these drugs can further reduce major adverse cardiovascular events (MACE) when added to baseline statin therapy (126, 127).”
Ho, A. K. H., Leow, A. S., Tan, S. M.-L., Sim, V. W. J., Yan, Q., Sia, C. H., Simon, O., & Poh, K.-K. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1815535
The return of “goals” in the 2026 ACC/AHA/Multisociety guideline on the management of dyslipidemia
Ahmad, Z., & Garg, A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.06.006
Bonanni, L., Cutolo, A., & Ferri, N. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07898-z · Cited by 1
Boretti, A. A. (2026) · Lipids · doi:10.1002/lipd.70068 · Cited by 1
Kataoka, Y., Nicholls, S. J., Kitahara, S., Katasako-Yabumoto, A., Funabashi, S., Mitsui, K., Murai, K., Iwai, T., Sawada, K., Matama, H., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.06.008
Effect of early versus delayed evolocumab treatment on complex coronary artery revascularization
Haller, P. M., Gaba, P., Thomas, C., Fagundes, A., Oyama, K., Furtado, R. H. M., Zelniker, T. A., Kuder, J., MURPHY, S., Verma, S., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag304
Zhang, T., Li, D., Ning, Y., Shi, J., & Hu, Y. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/8814045
Tada, H., Takeji, Y., & Takamura, M. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100575
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are widely used in this context, and their efficacy and safety profiles have been well documented [2,3].”
Crosti, C., Marchesin, A., Casula, M., Olmastroni, E., & Catapano, A. L. (2026) · European Atherosclerosis Journal · doi:10.56095/eaj.v5i1.124
The legacy of early PCSK9 inhibitors: less lipid, less metal
Mesnier, J., & Steg, P. G. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag332
Self-citation
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

